Treatment of Crohn's disease patients with infliximab is detrimental for the survival of Mycobacterium avium ssp. paratuberculosis within macrophages and shows a remarkable decrease in the immunogenicity of mycobacterial proteins | Zendy

Horacio Bach | Zendy; Greg Rosenfeld | Zendy; Brian Bressler | Zendy

Open Access

Treatment of Crohn's disease patients with infliximab is detrimental for the survival of Mycobacterium avium ssp. paratuberculosis within macrophages and shows a remarkable decrease in the immunogenicity of mycobacterial proteins

Author(s) -

Horacio Bach,

Greg Rosenfeld,

Brian Bressler

Publication year - 2012

Publication title -

journal of crohn s and colitis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.277

H-Index - 80

eISSN - 1876-4479

pISSN - 1873-9946

DOI - 10.1016/j.crohns.2012.01.011

Subject(s) - paratuberculosis , mycobacterium , microbiology and biotechnology , monoclonal antibody , immune system , mycobacterium avium subspecies paratuberculosis , crohn's disease , immunogenicity , biology , macrophage , cytokine , tumor necrosis factor alpha , antibody , immunology , mycobacterium smegmatis , disease , virology , medicine , mycobacterium tuberculosis , tuberculosis , bacteria , in vitro , pathology , biochemistry , genetics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research